J
Jessica A. Moerland
Researcher at Michigan State University
Publications - 11
Citations - 38
Jessica A. Moerland is an academic researcher from Michigan State University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 2, co-authored 5 publications receiving 11 citations.
Papers
More filters
Journal ArticleDOI
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
Ana S. Leal,Kayla Zydeck,Sarah Carapellucci,Lyndsey A. Reich,Di Zhang,Jessica A. Moerland,Michael B. Sporn,Karen T. Liby +7 more
TL;DR: Treatment with LG 268, a RXR agonist, can improve response to immune checkpoint blockade in HER2+ or triple-negative breast cancer, and data suggest that the use of LG268, the only rexinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma, can be improved.
Journal ArticleDOI
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Jessica A. Moerland,Di Zhang,Lyndsey A. Reich,Sarah Carapellucci,Beth Lockwood,Ana S. Leal,Teresa Krieger-Burke,Bilal Aleiwi,Edmund Ellsworth,Karen T. Liby +9 more
TL;DR: The results validate the screening paradigm for in vitro testing of novel rexinoids and demonstrate the potential for MSU-42011 to be developed for the treatment of KRAS-driven lung cancer.
Book ChapterDOI
Potential therapeutic uses of rexinoids
TL;DR: The essential roles that RXR and partner receptors play in T cells, dendritic cells, macrophages and epithelial cells, especially within the tumor microenvironment are described, and the promise of combining rexinoids with approved checkpoint blockade therapies in order to enhance efficacy of the latter and to delay or potentially eliminate drug resistance is supported.
Journal ArticleDOI
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.
Ana S. Leal,Jessica A. Moerland,Di Zhang,Sarah Carapellucci,Beth Lockwood,Teresa Krieger-Burke,Bilal Aleiwi,Edmund Ellsworth,Karen T. Liby +8 more
TL;DR: In this paper, MSU42011, a new retinoid X receptor (RXR) agonist, was used to modulate the tumor microenvironment in breast and lung cancer.
Journal ArticleDOI
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Di Zhang,Bijay Singh,Jessica A. Moerland,Owen Mitchell,Lizbeth Lockwood,Sarah Carapellucci,Srinivas Sridhar,Karen T. Liby +7 more
TL;DR: In this article, the PARP inhibitor talazoparib (TLZ) was implanted into spacer implants (InCeT-TLZ), where TLZ was released gradually over 30 days as implants degraded.